Navigating the Landscape of Neoadjuvant Immunotherapy for NSCLC: Progress and Controversies

Overview

Journal Ther Adv Med Oncol

Date 2025 Jan 9

PMID 39781239

Authors

Yuzhu Chen

Fei Qi

Chenhao Sun

Peng Jiang

Xiangyu Xue

Xiaomei Yang

Xiaomi Li

Xin He

Yishuo Wang

Tongmei Zhang

Affiliations

Soon will be listed here.

Abstract

Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context. Careful consideration is essential to maximize the benefits of immunotherapy for patients with resectable NSCLC. This article offers a detailed overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC. By examining these developments, we aim to provide new perspectives and valuable insights into the benefits and challenges of applying neoadjuvant immunotherapy in clinical settings.

References

Liu J, Blake S, Yong M, Harjunpaa H, Ngiow S, Takeda K . Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016; 6(12):1382-1399. DOI: 10.1158/2159-8290.CD-16-0577. View

Shao M, Yao J, Wang Y, Zhao L, Li B, Li L . Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial. Signal Transduct Target Ther. 2023; 8(1):146. PMC: 10083171. DOI: 10.1038/s41392-023-01355-1. View

Lui V, Karpuchas J, DENT P, McCulloch P, Blajchman M . Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. Br J Cancer. 1975; 32(3):323-30. PMC: 2024745. DOI: 10.1038/bjc.1975.230. View

Saerens M, Brusselaers N, Rottey S, Decruyenaere A, Creytens D, Lapeire L . Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. Eur J Cancer. 2021; 152:165-182. DOI: 10.1016/j.ejca.2021.04.034. View

Chaft J, Shyr Y, Sepesi B, Forde P . Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):546-555. PMC: 8853628. DOI: 10.1200/JCO.21.01589. View

Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W . Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024; 331(3):201-211. PMC: 10792477. DOI: 10.1001/jama.2023.24735. View

Yi Y, Shen L, Shi W, Xia F, Zhang H, Wang Y . Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study. Clin Cancer Res. 2020; 27(5):1329-1340. DOI: 10.1158/1078-0432.CCR-20-3445. View

Kang J, Zhang C, Zhong W . Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun (Lond). 2021; 41(4):287-302. PMC: 8045926. DOI: 10.1002/cac2.12153. View

Zhang F, Guo W, Zhou B, Wang S, Li N, Qiu B . Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2022; 17(7):909-920. DOI: 10.1016/j.jtho.2022.04.012. View

10.

. Neoadjuvant ICI Response, Microbiome Probed in NSCLC. Cancer Discov. 2021; 11(5):OF1. DOI: 10.1158/2159-8290.CD-NB2021-0324. View

11.

Zhao Z, Yang C, Chen S, Yu H, Lin Y, Lin Y . Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021; 10(1):1996000. PMC: 8547836. DOI: 10.1080/2162402X.2021.1996000. View

12.

Zhu Q, Chen G, Liu Y, Zhou Y . Neoadjuvant immunotherapy versus chemoimmunotherapy in non-small cell lung cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2023; 102(9):e33166. PMC: 9981425. DOI: 10.1097/MD.0000000000033166. View

13.

Caushi J, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue E . Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021; 596(7870):126-132. PMC: 8338555. DOI: 10.1038/s41586-021-03752-4. View

14.

Brown J, Sundar R, Lopez J . Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2017; 118(3):312-324. PMC: 5808021. DOI: 10.1038/bjc.2017.376. View

15.

Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A . SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021; 39(26):2872-2880. DOI: 10.1200/JCO.21.00276. View

16.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

17.

Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T . Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO). J Immunother Cancer. 2022; 10(10). PMC: 9594538. DOI: 10.1136/jitc-2022-005636. View

18.

Wang D, Wu X, Sun Y . Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022; 7(1):331. PMC: 9485144. DOI: 10.1038/s41392-022-01136-2. View

19.

Sands J, Mandrekar S, Kozono D, Oxnard G, Hillman S, Wigle D . Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021; 13(9):727-734. PMC: 8293026. DOI: 10.2217/imt-2021-0019. View

20.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View